Skip to content Skip to footer
Subscribe Now
Top Performing Drug – Enbrel (June Edition)
INSIGHTS+

Top Performing Drug – Enbrel (June Edition)

Shots: In continuation of our previous series on the top-performing drug of the month, based on 2021 revenue, this month we have covered Enbrel as the top-performing drug of the month Enbrel is a biologic drug classified as a TNF inhibitor used to treat rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and other autoimmune diseases PharmaShots…
June 28, 2023

Read more

Exclusive Coverage Global PHT Expo & Summit 2023
EVENTS

Exclusive Coverage: Global PHT Expo & Summit 2023

The 15th and 16th of February saw the Global PHT Expo & Summit taking place at the Hyatt Centric in New Delhi, India. Through Global PHT Summit, it was for the first time that the pharma, healthcare, and technology veterans, pioneers, and professionals converged on the same platform to impart their knowledge on the best & futuristic PHT practices. The theme of the event…
February 27, 2023

Read more

Top Performing Drug of 2021 – Eylea (September Edition)
INSIGHTS+

Top Performing Drug of 2021 – Eylea (September Edition)

Active Ingredient: Aflibercept Strength: 2 mg (0.05 mL) Dosage Form: Injection (intravitreal) Mechanism of Action: VEGF-A and PlGF inhibitors First Approval: US (18 Nov 2011), EU (27 Nov 2012) Revenue1 EYLEA net sales represent a significant portion of the total revenues for both Regeneron and Bayer. Both companies jointly commercialize the product Regeneron records net product sales of EYLEA in…
September 22, 2022

Read more

13th Summit on Biosimilars & Innovator Biologics
EVENTS

13th Summit on Biosimilars & Innovator Biologics

The American Conference Institute invites you to attend the 13th Summit on Biosimilars & Innovator Biologics on June 28-29, 2022, back in-person in Boston! Gain government and industry insights on the Innovator and Biosimilars Marketplace from the U.S. FTC, USPTO, AAM, BIO and leading In-House Counsel. We’ve reached an inflection point in the United States. With another major wave of loss…
May 23, 2022

Read more

Insights+ Key Biosimilars Events of May 2021
INSIGHTS+

Insights+ Key Biosimilars Events of May 2021

Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and the patients During the month of May, Samsung initiated patient enrollment in the P-III…
June 3, 2021

Read more

Insights+ Key Biosimilars Events of August 2020
INSIGHTS+

Insights+ Key Biosimilars Events of August 2020

Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency Mylan with its partner Lupin and Biocon launched Nepexto (biosimilar, etanercept) and Semglee (insulin glargine injection) in Germany & in the US, respectively. Additionally, Formycon and Bioeq planned to initiate P-III MAGELLAN-AMD Trial for its FYB203 (biosimilar,…
September 3, 2020

Read more

Insights+ Key Biosimilars Events of July 2020
INSIGHTS+

Insights+ Key Biosimilars Events of July 2020

Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency Cadila expanded its footprints in India with the launch of its two biosimilars Bevaro (bevacizumab, biosimilar) and Ritucad (rituximab, biosimilar) Our team at PharmaShots has summarized 9 key events of the biosimilar space of July 2020 1. Samsung…
August 7, 2020

Read more

Insights+ Key Biosimilars Events of June 2020
INSIGHTS+

Insights+ Key Biosimilars Events of June 2020

Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency Mylan with its partners Lupin and Biocon received MAA for Nepexto (biosimilar, etanercept) in EU and the US FDA's Approval for Semglee (biosimilar, insulin glargine) respectively Our team at PharmaShots has summarized 15 key events of the…
July 3, 2020

Read more

Load more